Cargando…

Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma

The purpose of the present study was to develop oral dispersible tablets containing prednisolone (PDS)-loaded chitosan nanoparticles using microcrystalline cellulose (MCC 101), lactose, and croscarmellose sodium (CCS). The PDS-loaded chitosan nanoparticles were formulated by ionotropic external gela...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi-Dan, Liang, Zhong-Yuan, Cen, Yan-Yan, Zhang, He, Han, Mei-Gui, Tian, Yun-Qiao, Zhang, Jie, Li, Shu-Jun, Yang, Da-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662371/
https://www.ncbi.nlm.nih.gov/pubmed/26640367
http://dx.doi.org/10.2147/DDDT.S86075
_version_ 1782403153667293184
author Chen, Yi-Dan
Liang, Zhong-Yuan
Cen, Yan-Yan
Zhang, He
Han, Mei-Gui
Tian, Yun-Qiao
Zhang, Jie
Li, Shu-Jun
Yang, Da-Sheng
author_facet Chen, Yi-Dan
Liang, Zhong-Yuan
Cen, Yan-Yan
Zhang, He
Han, Mei-Gui
Tian, Yun-Qiao
Zhang, Jie
Li, Shu-Jun
Yang, Da-Sheng
author_sort Chen, Yi-Dan
collection PubMed
description The purpose of the present study was to develop oral dispersible tablets containing prednisolone (PDS)-loaded chitosan nanoparticles using microcrystalline cellulose (MCC 101), lactose, and croscarmellose sodium (CCS). The PDS-loaded chitosan nanoparticles were formulated by ionotropic external gelation technique in order to enhance the solubility of PDS in salivary pH. Prepared nanoparticles were used for the development of oral fast disintegrating tablets by direct compression method. The prepared tablets were evaluated for disintegration time (DT), in vitro drug release (DR), thickness, weight variation, drug content uniformity, friability, and hardness. The effect of concentrations of the dependent variables (MCC, lactose, CCS) on DT and in vitro DR was studied. Fast disintegrating tablets of PDS can be prepared by using MCC, CCS, and lactose with enhanced solubility of PDS. The minimum DT was found to be 15 seconds, and the maximum DR within 30 minutes was 98.50%. All independent variables selected for the study were statistically significant. Oral fast disintegrating tablets containing PDS nanoparticles could be the better choice for the pediatric patients that would result in better patient compliance. From this study, it can be concluded that fast disintegrating tablets could be a potential drug delivery technology for the management of asthma in pediatrics.
format Online
Article
Text
id pubmed-4662371
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-46623712015-12-04 Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma Chen, Yi-Dan Liang, Zhong-Yuan Cen, Yan-Yan Zhang, He Han, Mei-Gui Tian, Yun-Qiao Zhang, Jie Li, Shu-Jun Yang, Da-Sheng Drug Des Devel Ther Original Research The purpose of the present study was to develop oral dispersible tablets containing prednisolone (PDS)-loaded chitosan nanoparticles using microcrystalline cellulose (MCC 101), lactose, and croscarmellose sodium (CCS). The PDS-loaded chitosan nanoparticles were formulated by ionotropic external gelation technique in order to enhance the solubility of PDS in salivary pH. Prepared nanoparticles were used for the development of oral fast disintegrating tablets by direct compression method. The prepared tablets were evaluated for disintegration time (DT), in vitro drug release (DR), thickness, weight variation, drug content uniformity, friability, and hardness. The effect of concentrations of the dependent variables (MCC, lactose, CCS) on DT and in vitro DR was studied. Fast disintegrating tablets of PDS can be prepared by using MCC, CCS, and lactose with enhanced solubility of PDS. The minimum DT was found to be 15 seconds, and the maximum DR within 30 minutes was 98.50%. All independent variables selected for the study were statistically significant. Oral fast disintegrating tablets containing PDS nanoparticles could be the better choice for the pediatric patients that would result in better patient compliance. From this study, it can be concluded that fast disintegrating tablets could be a potential drug delivery technology for the management of asthma in pediatrics. Dove Medical Press 2015-11-20 /pmc/articles/PMC4662371/ /pubmed/26640367 http://dx.doi.org/10.2147/DDDT.S86075 Text en © 2015 Chen et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Chen, Yi-Dan
Liang, Zhong-Yuan
Cen, Yan-Yan
Zhang, He
Han, Mei-Gui
Tian, Yun-Qiao
Zhang, Jie
Li, Shu-Jun
Yang, Da-Sheng
Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma
title Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma
title_full Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma
title_fullStr Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma
title_full_unstemmed Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma
title_short Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma
title_sort development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662371/
https://www.ncbi.nlm.nih.gov/pubmed/26640367
http://dx.doi.org/10.2147/DDDT.S86075
work_keys_str_mv AT chenyidan developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma
AT liangzhongyuan developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma
AT cenyanyan developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma
AT zhanghe developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma
AT hanmeigui developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma
AT tianyunqiao developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma
AT zhangjie developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma
AT lishujun developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma
AT yangdasheng developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma